ArticleOncoimmunology

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways.

Peng Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.